Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT05053386
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Epirubicin for the Treatment of Sepsis & Septic Shock
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT05033808
- Locations
- 🇩🇪
University Medicine Greifswald, Greifswald, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Germany
🇩🇪Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 33
- Registration Number
- NCT05024734
- Locations
- 🇨🇭
Roland Seiler, Biel, Switzerland
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04899570
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04877821
- Locations
- 🇨🇳
NeoSACT, Guangzhou, Guangdong, China
Pyrotinib in Combination with Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: a Phase II Trial
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 140
- Registration Number
- NCT04872985
- Locations
- 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 416
- Registration Number
- NCT04770272
- Locations
- 🇩🇪
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;, Bottrop, Germany
MicroRNA Profiles in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- University College Hospital, Ibadan
- Target Recruit Count
- 42
- Registration Number
- NCT04771871
- Locations
- 🇳🇬
Lagos State University Teaching Hospital, Lagos, Nigeria
🇳🇬Lagos University Teaching Hospital, Lagos, Nigeria
🇳🇬Obafemi Awolowo University Teaching Hospital, Ile-Ife, Oshun, Nigeria
Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 226
- Registration Number
- NCT04738188
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, China
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2021-06-04
- Target Recruit Count
- 60
- Registration Number
- NCT04717531
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.